Texas is currently home to 4884 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Recruiting
To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms, IDH1-mutated Higher-Risk Myelodysplastic Syndromes
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Recruiting
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
The Impact of KETO5 XOGenius Beverage on Markers of Physiological and Neurocognitive Health
Recruiting
The primary objectives of this application are to 1) investigate the effect of increased daily consumption of the Keto5 XOGenius beverage on outcomes associated with elevated risk for various neurocognitive and pathophysiological conditions/diseases. And 2) to investigate the effect of daily consumption of the Keto5 XOGenius beverage on the following variables: waist circumference, body weight, and body mass index (BMI).
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/26/2025
Locations: UT Arlington - Science and Engineering Innovation and Research Building, Arlington, Texas
Conditions: Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Recruiting
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/26/2025
Locations: University of Texas, Dell Children's, Austin, Texas
Conditions: Microcystic Lymphatic Malformation
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
Recruiting
The EMPoWER Study randomized clinical trial is a strengths-based behavioral intervention delivered to youth with type 1 diabetes (age 10 to 13) and their parents. The purpose of the intervention is to improve glycemic, behavioral, and psychosocial outcomes in youth with diabetes using a multiple systems approach that engages youth, their parents, and diabetes care providers to identify and build youths' diabetes strengths. The primary aim of this study is to assess the intervention impact on gly... Read More
Gender:
ALL
Ages:
Between 10 years and 99 years
Trial Updated:
03/26/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Type 1 Diabetes
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Recruiting
This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Saint David's HealthCare Partnership, L.P., LLP, Austin, Texas
Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Recruiting
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: The University of Texas Health Science Center at Houston, Bellaire, Texas
Conditions: Pyoderma Gangrenosum
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Recruiting
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, Recurrent Glioma
A Retrospective Assessment of OviTex PRS (OviTex)
Recruiting
The objective of this retrospective-prospective, observational study is to evaluate the safety profile overall and within two device types of OviTex PRS in previous pre-pectoral or sub-pectoral implant-based breast reconstructions.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Dermatology Associates of San Antonio/Baptist Medical Center, San Antonio, Texas
Conditions: Reconstructive Surgical Procedures
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/26/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Early Alzheimer's Disease
Outcomes of Focal Ablation for Prostate Cancer
Recruiting
This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.
Gender:
MALE
Ages:
Between 18 years and 90 years
Trial Updated:
03/26/2025
Locations: UTSW, Dallas, Texas
Conditions: Prostate Cancer
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
Recruiting
This is a single arm, single-center, prospective clinical trial designed to track the peri, post-operative and oncologic outcomes when utilizing the da-Vinci single port (SP) robotic platform to perform robotic nipple sparing mastectomy (rNSM) and immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (ADM - Alloderm), for patients with breast cancer as well as those with a high risk for breast cancer. Safety and feasibility measures will be measured as prima... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
03/26/2025
Locations: UT Southwestern, Dallas, Texas
Conditions: Breast Cancer, High Risk of Breast Cancer